Open | - |
Close | - |
Volume / Avg. | 0 / 435.522K |
Day Range | - - - |
52 Wk Range | 1.240 - 4.068 |
Market Cap | $112.170M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 11.44% |
Days to Cover | 8.43 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of BioAtla (NASDAQ: BCAB) through any online brokerage.
Other companies in BioAtla’s space includes: Vincerx Pharma (NASDAQ:VINC), Outlook Therapeutics (NASDAQ:OTLK), Anixa Biosciences (NASDAQ:ANIX), Barinthus Biotherapeutics (NASDAQ:BRNS) and Vistagen Therapeutics (NASDAQ:VTGN).
The latest price target for BioAtla (NASDAQ: BCAB) was reported by JMP Securities on Tuesday, December 5, 2023. The analyst firm set a price target for 12.00 expecting BCAB to rise to within 12 months (a possible 412.82% upside). 17 analyst firms have reported ratings in the last year.
The stock price for BioAtla (NASDAQ: BCAB) is $2.34 last updated March 18, 2024 at 4:02 PM EDT.
There are no upcoming dividends for BioAtla.
BioAtla’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for BioAtla.
BioAtla is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.